Good morning. Before I turn the call over to management, I would like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, product initiatives, including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.
These statements are based on currently available information and management's current assumptions, expectations, and projections of future events. While management believes its assumptions, expectations, and projections are reasonable in the view of currently available information, you are cautioned not to place undue reliance on these forward-looking statements. The company's actual results may differ materially from those discussed during this webcast for a variety of reasons, including those described in the forward-looking statements and risk factor section of the company's 10-K form for the year 2025, which was filed with the SEC on April 7th, 2026. Its other filings with the SEC, which are available on the investor relations section of Jaguar's website.
Except as required by law, Jaguar undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events, or otherwise. Additionally, please note that the company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP Recurring EBITDA. Jaguar believes that the disclosure items on these non-GAAP measures provide investors with additional information that reflects the basis upon which the company's management assesses and operates the business.
These non-GAAP financial measures should not be viewed in isolation or as substitutes for GAAP net sales, GAAP net loss, and are not substitutes for or superior to measures of financial performance in conformity with GAAP. Today's conference is being recorded. At this time, it is my pleasure to turn the call over to Lisa Conte, Jaguar Health's founder, president, and chief executive officer. Lisa, the floor is yours.
Thank you, Sherry. Thank you, everybody, for joining the investor webcast today. As you heard, my name is Lisa Conte. I am the founder, president, and CEO of Jaguar Health and our wholly owned subsidiary, Napo Pharmaceuticals. I am also the chairman of our Italian subsidiary, Napo Therapeutics. As usual, I may use the words Jaguar and Napo interchangeably when I am referring to the company. After I speak today, our CFO, Carol Lizak, will provide a recap of the financial highlights for the third quarter of 2026.
One key highlight that I want to highlight, Jaguar significantly reduced its outstanding debt balance by over $10 million in the third quarter of 2026. Once again, the theme of today's webcast is transformational near-term catalysts and sharp strategic focus. If you have followed the company in the past, you may recall that in January of 2026, we completed what we consider a transformative transaction, the signing of a U.S. commercial out-license agreement with Future Pak for Mytesi, the brand name of our FDA-approved formulation of crofelemer for adults living with HIV/AIDS and diarrhea.
Included in that license also was Canalevia-CA1, our conditionally FDA-approved formulation of crofelemer for doggies with chemotherapy-induced diarrhea. We made this strategic decision to out-license Mytesi to Future Pak first because they had recently acquired Theratechnologies, an HIV-focused commercial company with more than four times the commercial effort of Jaguar in the United States. The HIV space, and they're focused completely in the U.S. HIV space, and they have other HIV-related products.
Secondly, this fulfilled our strategic plan to bring in meaningful non-dilutive dollars to help fund our sharp development focus on our late-stage clinical development program for a novel proprietary powder for oral solution formulation of crofelemer. Significance of the novel formulation is that this is a different product, a whole different business structure of crofelemer, specifically for rare intestinal failure indications. Same active ingredient, same product, certain manufacturing activities are common to Mytesi, yet a different formulation for the rare intestinal failure indications.
Rare, meaning we have orphan drug designation for the intestinal failure indications, two different indications in both the United States and Europe. While Jaguar, Napo, remains the manufacturer of Mytesi and Canalevia-CA1, therefore supplying the product to Future Pak at a cost-plus term, so a profit center there, we are now fully a rare disease GI company with 100% of our human development efforts sharply and strategically focused on this rare disease program.
For many years prior to the out-license agreement with Future Pak, we were selling Mytesi ultimately into the distributors and had a sales force promoting directly to the physicians who were prescribing Mytesi to patients, and the expense associated with that, and the expense associated with a single product as opposed to the Theratech situation right now. At this point, we are operating as a supplier of Mytesi to Future Pak, and therefore a much different impact on the reporting of sales and the revenue numbers that we are reporting, but a different impact on the non-dilutive dollars that we receive from that agreement. Back to our main strategic focus.
Our ultimate strategy continues to involve evaluating strategic alternatives driven by the tremendous value to potential development and a commercialization partner for our rare disease intestinal failure program, for our late-stage rare disease intestinal failure program. Just to put this in perspective, the out-license to Future Pak was $18 million upfront, primarily for the U.S. HIV market, a market with a peak annual market opportunity of maybe $50 million-$70 million annually.
The global market for short bowel syndrome, which includes our bowel syndrome with intestinal failure, as well as some rare congenital disorders, is estimated to reach more than $8 billion in 2033, according to third-party market research. A different third-party market research estimates the value of just the global MVID marketplace, which is an ultra-rare indication for which there are no treatments, nothing in clinical development t hey put that estimate at over $2 billion by 2032.
Again, our strategic goal is to again bring in non-dilutive dollars from a strategic partner, as we did with Future Pak for Mytesi. Market differences are in the tens of millions for Mytesi for HIV U.S. versus billions for intestinal failure globally. I just referred to MVID. It's pediatric microvillus inclusion disease, as I mentioned, an ultra-rare disorder, no approved therapies, a lethal natural history. This is Jaguar's very near-term value driver in the intestinal failure program. It's our lead target indication. We have completed enrollment in a pivotal trial, a blinded pivotal trial to support a targeted new drug application submission in mid-2027.
We're talking like eight, nine, 10 months away. This is very exciting, meaningful to MVID patients, and the catastrophic impact to their health, and to the impact on their family and other supportive caregivers, of which there are many for MVID patients. As awareness in crofelemer's impact grows with respect to our compassionate use patients, which has been published and presented at various medical conferences, we've experienced many patient and physician inquiries for future possibility for access to crofelemer.
Short bowel syndrome, which you'll hear me refer to as SBS or SBS-IF, short bowel syndrome with intestinal failure, represents a larger follow-on indication using the same dosage formulation and the same physiological mechanism for intestinal failure as with MVID patients. SBS and MVID are both separate rare disease orphan designations, each in the U.S. and Europe. Our intestinal failure program represents a blockbuster global market opportunity, first and foremost in terms of addressing the catastrophic unmet medical need in patients, blockbuster in terms of the beneficial impact to morbidity and mortality, and the cost to the healthcare system, and then also the financial return opportunity for all stakeholders, including our shareholders.
This return opportunity, of course, is especially important to the motivation and the incentive to potential corporate partners and strategic alternatives that we are looking at. As I mentioned, the global market for SBS-IF is estimated at over $8 billion, again by a third party in 2033, MVID over $2 billion. I want to take a moment to describe not just dollars, but the catastrophic impact of intestinal failure on patients and what this means for their caregiving community, which includes family members, healthcare professionals, nurses, nutritionists, others. It does take a village to manage these situations.
Intestinal failure, it's a debilitating condition that often requires patients to receive life-sustaining fluids, electrolytes, IV administration for the nutrients of life, which is all encompassed in something called TPN, total parenteral nutrition. Total parenteral nutrition with supplemental fluids is called parenteral support. This is IV nutritional support, IV nutritional support. Many intestinal failure patients require this parenteral support up to 20 hours a day, seven days a week. IV nutrition. So obviously, this is a catastrophic situation for the patient, both from a healthcare standpoint and the obvious impact on quality of life.
Parenteral support is supportive, it is necessary for life, it is sustenance, yet it is associated with quite serious complications, including liver and kidney toxicities, compromised cognitive functioning, negative impact on growth, infections, line infections from being on IV nutrition, and ultimately, not just the morbidity aspects of all that, but mortality as well. This is why standard of care parenteral support, TPN, is referred to as lethal natural history for these patients. And the cost is meaningful. It is estimated at about $500,000 a year in the United States per patient, and the cost to the healthcare system is inevitably higher, can top $1 million per year per patient due to the complications of infections and keeping that balance of nutrients of life correct.
And this is all on top of the mortality risk. MVID is a congenital disease, so the patient, the infant, the baby, is born and has massive diarrhea and is unable to absorb nutrients of life. If the baby is not diagnosed immediately, the newborn, they often die right away. If the newborn is diagnosed, they will be on parenteral support for the rest of their life. Again, up to seven days a week, 20 hours a day. The key of what we are looking for in providing adjunctive therapy to these patients is a reduction in the amount of time they are on parenteral support. Parenteral support is life-sustaining, but can we reduce the amount of time that they are on parenteral support and therefore have a significant impact on the massive toxicities and comorbidities that are life-shortening for these patients, and in this case, for these infants?
Even a reduction of 5%-10% is considered clinically meaningful. Remember, these are infants, enabling the baby to grow to a child and thrive is life and disease altering and altering for the family condition as well. So, the endpoint in the crofelemer clinical development program is, in fact, the reduction in parenteral support. Let us say even 10%-15%. That would allow the patient to receive a significant percentage of their parenteral support at night while sleeping, preserving some quality of life, the ability to go to school during waking hours. The patient would not need to be attached to an IV to go through some of their normal activities of daily living, and that, of course, reduces the situation and the environment and the circumstances for infection as well.
Keeping in mind that number of 5%, 10%, 15% is meaningful, this past June, we presented groundbreaking results at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology, and Nutrition meeting. This was in Lille, France i t is referred to as ESPGHAN. In that presentation, in an MVID patient, the weekly parenteral support requirements normalized to body weight were reduced by up to 48%. Remember, 10%-15% is considered clinically meaningful. 48% following more than 12 months of crofelemer therapy with no safety issues.
We also presented two short bowel syndrome IF pediatric patients, and the PS requirements normalized to body weight were reduced by up to 40%, again, for over a year of treatment with no safety issues. These results are stunning. It's hard to express, it's hard to communicate how clinically relevant this is and how rewarding it is for all involved to see these patients, these children, that are thriving, and why there is so much awareness growing in the intestinal failure community.
What was really powerful and additionally powerful is that after these patients were treated for about three months, they were, per the protocol, taken off crofelemer, and they immediately relapsed and needed to be put back on crofelemer, one of the strongest trial design parameters to demonstrate the true efficacy of a product. These patients have now continued to be treated for over a year, and we expect they'll be on crofelemer for the rest of their lives, and we take great pride and honor in providing the product for that.
There have been no crofelemer-related safety issues in our intestinal failure patients, in any patient that we've treated with anything, and this is very consistent with crofelemer in thousands of patients that have been in clinical trials or have accessed the product that is now commercialized. A hallmark of crofelemer is this safety profile, and we should never take it for granted, because one of the most common reasons why new drug applications fail is because of a safety issue. As a reminder, drugs are approved by the FDA. New drug applications are approved by the FDA on their benefit-risk ratio.
When the risk is zero, the benefit exists into perpetuity. In the program, in addition to these compassionate use programs or expanded access, they have different names that we have presented. Additionally, we've completed enrollment in a blinded clinical trial for MVID. The trial is taking place at clinical sites in the U.S., Italy, and the UAE, United Emirates, anyway, in Dubai and Abu Dhabi. In support of our planned new drug application filing in patients in this trial, we submitted an amendment, and we did receive FDA authorization for a treatment-only extension phase of the trial after the placebo phase of the trial.
This was announced this past September. All of the randomized pediatric MVID patients in this trial have entered the single-blind extension phase, are receiving crofelemer at this time. This is the powder for oral solution, and this is as adjunctive therapy to their parenteral support, allows the patients to benefit from the product, and allows us to collect additional safety information, very important for a new drug application, as well as continued efficacy.
With the data from the patients in this extension and the early access compassionate use patients that I previously discussed, where the data has been presented, we're talking about the opportunity for the new drug application for MVID, this ultra-rare disease, mid-2027, with essentially 3%-4% of the patient population, which is a typical percentage of treatment across almost any indication in clinical trial, pivotal drug trials.
For us, this is literally a single-digit number of patients and shows the efficiency of orphan drug indications and ultra-rare indications. Also in 2027, we plan to submit an application for breakthrough therapy designation from the FDA for crofelemer for MVID in the U.S. If we achieve such designation from the FDA, this gives us the opportunity for review upon filing the new drug application of perhaps just four months, which could make the product approval in the end of 2027 possible. I am going to move to the adult patient program.
Last month, at the American College of Gastroenterology Annual Scientific Meeting, we presented, or positive preliminary results were presented by an investigator for the ongoing open-label third-party pilot study of crofelemer, again, the same powder for oral solution in adult patients with type 1 short bowel syndrome with intestinal failure. Intestinal failure in short bowel syndrome is the same clinical situation as intestinal failure in MVID children. Short bowel syndrome patients are unable to absorb the nutrients of life because they literally have a short bowel. There is not enough surface area. A normal intestine is about 20 to 25 feet.
An SBS-IF intestine may be five feet or less. They too end up on parenteral support, again, up to 20 hours a day, seven days a week, with the same comorbidities associated with that TPN parenteral support, the same catastrophic toxicities that I have previously described in the MVID patients. It is because of the TPN and the parenteral support. Additionally, we have ongoing right now a phase II randomized double-blind placebo-controlled trial with this formulation of crofelemer, the same one that is in MVID, at various sites in Germany and Italy for SBS-IF in adult patients.
SBS-IF is still an orphan indication, though a larger patient population of MVID. MVID arises from congenital abnormalities. SBS can also result from congenital abnormalities, yet also surgical resection due to Crohn's disease, ischemia, cancer. Cancer is about a third of the patients. Trauma, accidents. Adults and pediatric SBS-IF patients also face chronic dependence on parenteral support, the associated morbidity, and mortality risks. In the U.S., that population is about 12,000 people. The NDA for MVID, that is for MVID, is targeted mid-2027, as I mentioned, and we expect this filing to be coincident with the timing of the availability of the results, the unblinding of the results from the phase II study with short bowel syndrome in adults.
MVID is an important stepping stone to our planned pathway for ultimate approval of crofelemer for SBS. Important and crucial, first and foremost, for patient benefit and access for MVID for those babies, but also for the company strategy to enter a blockbuster indication with no alternative treatments, dramatic unmet medical need. The safety data for MVID and SBS would be the same. Manufacturing, it is the same formulation, would be the same.
The two most common reasons why new drug applications fail would be addressed by this first approval for MVID, potential approval for MVID, again, the stepping stone into SBS. From a standpoint of competition, there is nothing out there for MVID. There is nothing out there in development. There is nothing for these patients beyond parenteral support, and this, of course, would be adjunctive therapy to the life-sustaining parenteral support, but hopefully in a more manageable way. In SBS, there is a product approved. It is called a GLP-2 approach, not GLP-1. That is the weight loss thing. GLP-2 is essentially a growth hormone, and what the mechanism is doing is attempting to grow the intestine a bit so that parenteral support can be reduced by maybe 10%-15%. If you remember, those numbers are what is considered clinically irrelevant.
Again, we far exceeded that reduction with the 40%-45% in both the MVID and the short bowel syndrome compassionate use expanded access patients that have already been reported. GLP-2 growth hormone for SBS is not standard of care. It's utilized in like 5%-7% of the patients. There's many, many side effects, and it's a growth hormone. You can't use a growth hormone, for example, in cancer patients. You don't want to encourage growth in a hyperproliferative abnormal situation, and cancer is about a third of the short bowel syndrome patients. Nevertheless, what GLP-2s have done is established a business model and a regulatory approval benchmark. GLP-2s are reimbursed at the rate of about $500,000 per year in the U.S., and they were approved with a clinical benefit of about 10%-15% reduction in parenteral support.
Crofelemer, on the other hand, we are seeking to have that become standard of care for intestinal failure, first in MVID, then in SBS-IF, and there's many other intestinal failure TPN/PS-dependent patient populations in the future. With the clinical proof of concept data we have in hand and the very, very near-term clinical and regulatory milestones ongoing, we're confident in our ability to execute our business development goals in our intestinal failure program and further our program and our strategy and how we have executed in the past to bring in serious, meaningful, valuable, non-dilutive dollars commensurate with the market size, addressing the serious unmet medical need, driven first and foremost by the benefit and the benefit-risk, with the risk being nearly zero, that providing to patients with no alternative treatment, and all the business benefits that come from that as well.
I should mention the major focus of our business overwhelmingly is human health, and of course, the rare disease program is 100% of that human focus. Yet we do have a small business in animal health, and we are pleased to announce recently that Neonorm Dog, that's the product name, Neonorm Dog, is now available from Amazon. We expect it to be available fairly soon from other animal health channels with great access, and it's an absolutely fantastic opportunity for pet owners and veterinarians to access animal health products. Neonorm Dog is an extension of Jaguar's non-prescription Neonorm franchise, so it's an extension into companion animals. Neonorm franchise currently includes Neonorm for foals, horses, foals, and calves. It's a plant-based product to support proper hydration and bowel health in pre-weaned foals and calves.
Neonorm Dog is access to a plant-based non-prescription product to support normal stool consistency and GI fluid balance in dogs. With Neonorm Dog in particular, we're leveraging the relationships that we, Jaguar, built over the years when we were promoting and educating around Canalevia-CA1, our prescription product for chemotherapy-induced diarrhea in dogs, which now is licensed and promoted and educated by Future Pak. The Neonorm franchise, I'll actually conclude at that point. With this overview, you can hear we're very excited, very enthused, very busy, very focused with what we're doing, in particular with the IF program. I'm going to hand the discussion now over to Carol Lizak, our CFO, and let her give a recap of the financial highlights, including the very, very meaningful and important reduction in debt that we achieved in the third quarter of this year. Carol, on to you.
Well, thank you, Lisa, and thank you to all of you who have joined our webcast today. I will begin my review of our financials for the third quarter of 2026. As Lisa mentioned, Jaguar entered into a U.S. commercial licensing agreement in January 2026 with Future Pak. Jaguar remains the manufacturer of Mytesi and Canalevia-CA1, supplying the products to Future Pak at cost-plus terms, and now operates as a distribution entity for Mytesi and Canalevia-CA1, with a primary focus on research and development efforts related to the company's late-stage development program for its powder-for-oral solution formulation of crofelemer for rare disease indications related to intestinal failure in humans. As announced in August 2026, Jaguar satisfied the closing conditions required to receive payment of the non-dilutive approximately $1.8 million holdback amount of the upfront fee from Future Pak.
Additionally, the company recognized license fees of $42,000 in the third quarter of 2026 from a securities purchase agreement with a European partner, which was supported by a binding term sheet. As of September 30, 2026, the total deferred revenue associated with this contract amounted to $425,000. There was no federal grant revenue recognized in the third quarter of 2026 for the clinical study related to the treatment of chemotherapy-induced diarrhea in dogs, and 25,520 in the month period ended September 30, 2026. The total net revenue for the company's prescription products was approximately $500,000 in the third quarter of 2026, which was comprised primarily of sales of Mytesi at cost plus for Future Pak. Under the royalty-free license agreement with Future Pak, all revenues generated in the United States from Mytesi and Canalevia-CA1, effective from January 12, 2026, have been directed to Future Pak.
Future Pak is privately held and does not report Mytesi sales. The total net revenue for the company's prescription products in the second quarter of 2026 was approximately $1.2 million. Compared to the third quarter of 2025, the number of Mytesi bottles the company sold in the third quarter of this year increased significantly, but commercial costs were substantially decreased. Prescription products net revenue in the third quarter of last year, when the company had a sales force and was focused on commercial sales of Mytesi, was approximately $3 million. The loss from operations decreased by $1.2 million, going from a loss of $7.2 million in the quarter ended September 30, 2025, to a loss of $6 million in the third quarter ended September 30, 2026.
This change was primarily due to a $700,000 decrease in total net revenue, which was offset by a reduction in operating expenses of approximately $2 million attributed to the Future Pak licensing agreement. Net loss decreased by approximately $3.8 million from a loss of $9.6 million in the quarter ended September 30, 2025, to a loss of $5.8 million in the quarter ended September 30 this year. In addition to the loss from operations, interest expense increased by $150,000 from $6,000 of interest income for the quarter ended September 30, 2025, to $156,000 in the quarter ended September 30 this year due to interest expenses accrued on notes.
The fair value of financial and hybrid instrument designation at fair value option, or what we call FVO, decreased by about $2.2 million from a loss of $2.3 million in the quarter ended September 30, 2025, to a loss of $96,000 in the same period in 2026. This is primarily due to lower outstanding carrying amounts of royalty interests and notes payable designated at FVO relative to their fair values, resulting in lower fair value changes during the period. Gain on extinguishment of debt increased by $600,000 from zero in the three months ended September 30, 2025.
The increase was primarily attributable to the extinguishment of the Streeterville note following the company's exchange transaction in which the company issued shares of its common stock to Streeterville, resulting in the full repayment and cancellation of the Streeterville new note. Non-GAAP recurring EBITDA for the third quarters of 2026 and 2025 were a net loss of approximately $5 million and $9 million respectively. That concludes my recap of high-level financials for the third quarter of 2026. I will now hand the discussion back to Lisa. Thank you.
Thanks, Carol. Strategically, expect business updates in the near future as we continue to evaluate business development and other strategic alternatives driven by the ongoing and very near-term catalysts in our rare disease program. This concludes our webcast for today. Thank you very much for joining. Thank you very much for those who have followed us for some time. I wish you all a wonderful, those in the U.S., wonderful Thanksgiving holiday with your families, and we'll see you next quarter. Bye-bye.
Thank you. This concludes our webcast. You may disconnect at this time.